scholarly journals Hurthle Cells Adenoma With Distant Metastases Refractory to Radioiodine

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A890-A891
Author(s):  
Pedro Weslley Rosario ◽  
Gabriela Franco Mourão
Keyword(s):  
Fdg Pet ◽  
Vascular Invasion ◽  
Progressive Increase ◽  
Whole Body ◽  
Serum Calcitonin ◽  
Pet Ct ◽  
Endocrine Organs ◽  
Hurthle Cells ◽  
Hürthle Cells ◽  
Fdg Pet Ct

Abstract Introduction: Adenoma of the thyroid is defined as an encapsulated follicular tumor that is well delimited in relation to the adjacent parenchyma and whose cells do not exhibit the nuclear alterations of papillary thyroid carcinoma (PTC), and in the absence of capsular and vascular invasion. Adenoma, including the of Hurthle cells, is considered a benign tumor. No additional treatment is recommended after resection of the tumor. Case: A 64-year-old man was submitted to total thyroidectomy because of a nodule measuring 3.5 cm with indeterminate cytology (predominance of Hurthle cells). Histology revealed an Hurthle cells adenoma of 3.2 cm. The tumor did not exhibit vascular or capsular invasion, the cells did not contain nuclei of PTC, and no necrosis or mitoses were observed. Five years after surgery, serum thyroglobulin (Tg) was elevated (25 ng/ml) during euthyroidism (TSH 0.6 mUI/l) and in the absence of anti-Tg antibodies. Serum calcitonin was undetectable. The patient developed a progressive increase in Tg and neck ultrasonography (US), chest computed tomography (CT), and FDG-PET/CT were performed. US revealed atypical lymph nodes (the largest with 12 mm) and cytology showed abundance of Hurthle cells. Chest CT detected multiple nodules, the largest measuring 15 mm, and FDG-PET/CT revealed areas of cervical and pulmonary uptake corresponding to the lesions seen on US and CT. The patient received 100 mCi radioactive iodine and post-therapy whole-body scanning showed mild uptake only in the thyroid bed. The patient continues to show progressive increase in Tg (last measurement > 1,000 ng/ml), as well as progression of metastases. He remains under follow-up and on therapy with tyrosine kinase inhibitor. The histology result was revised by two pathologists with broad experience in thyroid pathology who confirmed the initial findings compatible with adenoma. Conclusion: The present case shows that, although rare, Huthle cells tumors can develop metastases even when the tumor is < 4 cm and unequivocally without nuclei of PTC or capsular and vascular invasion, thus considered benign (adenoma). As observed in this case, these metastases can be macrometastases, distant, and refractory to radioiodine. Reference: Lloyd RV, Osamura RY, Klöppel G, Rosai J, ed. WHO Classification of Tumours of Endocrine Organs. 4th edition Lyon: IARC; 2017

scholarly journals F-18 FDG-PET-CT in the Diagnostic of a Late Medullary Thyroid Carcinoma Recurrence in a Patient with Follicular-Papillary Thyroid Cancer

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
Doina Piciu ◽  
Andra Piciu
Keyword(s):  
Thyroid Carcinoma ◽  
Papillary Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Fdg Pet ◽  
Whole Body ◽  
Serum Calcitonin ◽  
Medullary Thyroid ◽  
Superior Mediastinum ◽  
Pet Ct ◽  
Fdg Pet Ct

Mixed medullary and follicular or papillary carcinoma of thyroid is an extremely rare tumor, characterized by coexistence of morphological and immunohistochemical features of both medullary carcinoma and follicular (or papillary) carcinoma. This case report describes for the first time in the indexed database a late recurrence of a medullary thyroid carcinoma initially diagnosed as follicular-papillary form, treated and monitored accordingly. After 14 years, a superior mediastinum tumor was discovered incidentally at a thorax computer tomography. The whole-body I-131 scan was negative and F-18 FDG-PET-CT showed glucose avidity of the tumor. The patient was operated on and the histology revealed medullary thyroid carcinoma. If there are no possibilities to have routinely extensive immunohistologic profiles, it is recommended to check the serum calcitonin, at least in any patient with confirmed thyroid carcinoma.

scholarly journals Multi-task weak supervision enables anatomically-resolved abnormality detection in whole-body FDG-PET/CT

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Sabri Eyuboglu ◽  
Geoffrey Angus ◽  
Bhavik N. Patel ◽  
Anuj Pareek ◽  
Guido Davidzon ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Location Estimation ◽  
Supervised Machine Learning ◽  
Whole Body ◽  
Free Text ◽  
Abnormality Detection ◽  
Weak Supervision ◽  
Radiology Reports ◽  
Pet Ct ◽  
Fdg Pet Ct

AbstractComputational decision support systems could provide clinical value in whole-body FDG-PET/CT workflows. However, limited availability of labeled data combined with the large size of PET/CT imaging exams make it challenging to apply existing supervised machine learning systems. Leveraging recent advancements in natural language processing, we describe a weak supervision framework that extracts imperfect, yet highly granular, regional abnormality labels from free-text radiology reports. Our framework automatically labels each region in a custom ontology of anatomical regions, providing a structured profile of the pathologies in each imaging exam. Using these generated labels, we then train an attention-based, multi-task CNN architecture to detect and estimate the location of abnormalities in whole-body scans. We demonstrate empirically that our multi-task representation is critical for strong performance on rare abnormalities with limited training data. The representation also contributes to more accurate mortality prediction from imaging data, suggesting the potential utility of our framework beyond abnormality detection and location estimation.

Evaluation of 18 F-FDG PET/MRI, 18 F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer

2016 ◽  
Vol 85 (2) ◽  
pp. 459-465 ◽  
Author(s):  
Lino M. Sawicki ◽  
Johannes Grueneisen ◽  
Benedikt M. Schaarschmidt ◽  
Christian Buchbender ◽  
James Nagarajah ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Fdg Pet ◽  
Recurrent Breast Cancer ◽  
Whole Body ◽  
Pet Ct ◽  
Recurrent Breast ◽  
Fdg Pet Ct

scholarly journals Traumatic myositis ossificans: multifocal lesions suggesting malignancy on FDG-PET/CT—a case report

2020 ◽  
Vol 50 (1) ◽  
pp. 249-254
Author(s):  
Miho Sasaki ◽  
Yuka Hotokezaka ◽  
Reiko Ideguchi ◽  
Masataka Uetani ◽  
Shuichi Fujita
Keyword(s):  
Case Report ◽  
Fdg Pet ◽  
Myositis Ossificans ◽  
Whole Body ◽  
Left Cheek ◽  
Multiple Fractures ◽  
Fdg Uptake ◽  
Pet Ct ◽  
Multiple Regions ◽  
Fdg Pet Ct

AbstractMyositis ossificans (MO) is a benign soft-tissue lesion characterized by the heterotopic formation of the bone in skeletal muscles, usually due to trauma. MO is occasionally difficult to diagnose because of its clinical and radiological similarities with malignancy. We report a case of traumatic MO (TMO) in the masseter and brachial muscles of a 37-year-old man who presented with painless swelling in the left cheek and severe trismus. Due to the absence of a traumatic history at the first consultation and identification of a tumorous lesion in the left masseter muscle by magnetic resonance imaging (MRI), the lesion was suspected to be a malignant tumor. Subsequently, 18F-fluorodeoxyglucose positron-emission tomography/computed tomography (FDG-PET/CT) showed multiple regions of high FDG uptake across the whole body, suggestive of multiple metastases or other systemic diseases. However, intramuscular calcifications were also observed in the left masseter and brachial muscles, overlapping the areas with high FDG uptake. Moreover, multiple fractures were seen in the rib and lumbar spine, also overlapping the areas with high FDG uptake. Based on these imaging findings, along with a history of jet-ski trauma, TMO was suspected. The left cheek mass was surgically excised and histologically diagnosed as TMO. In this case report, FDG-PET/CT could detect multiple TMOs across the whole body. To the best of our knowledge, cases of multiple TMOs located far apart in different muscles are rare, and this may be the first report.

Low positive yield from routine inclusion of the brain in whole-body 18F-FDG PET/CT imaging for noncerebral malignancies

2013 ◽  
Vol 34 (6) ◽  
pp. 540-543 ◽  
Author(s):  
Kuruva Manohar ◽  
Anish Bhattacharya ◽  
Bhagwant R. Mittal
Keyword(s):  
Fdg Pet ◽  
Ct Imaging ◽  
Whole Body ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
The Brain

scholarly journals Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma

2021 ◽  
Author(s):  
Olwen Westerland ◽  
◽  
Ashik Amlani ◽  
Christian Kelly-Morland ◽  
Michal Fraczek ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Clinical Data ◽  
Bone Disease ◽  
Fdg Pet ◽  
Diagnostic Performance ◽  
Whole Body ◽  
Bone Lesions ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Abstract Purpose Comparative data on the impact of imaging on management is lacking for multiple myeloma. This study compared the diagnostic performance and impact on management of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and whole-body magnetic resonance imaging (WBMRI) in treatment-naive myeloma. Methods Forty-six patients undergoing 18F-FDG PET/CT and WBMRI were reviewed by a nuclear medicine physician and radiologist, respectively, for the presence of myeloma bone disease. Blinded clinical and imaging data were reviewed by two haematologists in consensus and management recorded following clinical data ± 18F-FDG PET/CT or WBMRI. Bone disease was defined using International Myeloma Working Group (IMWG) criteria and a clinical reference standard. Per-patient sensitivity for lesion detection was established. McNemar test compared management based on clinical assessment ± 18F-FDG PET/CT or WBMRI. Results Sensitivity for bone lesions was 69.6% (32/46) for 18F-FDG PET/CT (54.3% (25/46) for PET component alone) and 91.3% (42/46) for WBMRI. 27/46 (58.7%) of cases were concordant. In 19/46 patients (41.3%) WBMRI detected more focal bone lesions than 18F-FDG PET/CT. Based on clinical data alone, 32/46 (69.6%) patients would have been treated. Addition of 18F-FDG PET/CT to clinical data increased this to 40/46 (87.0%) patients (p = 0.02); and WBMRI to clinical data to 43/46 (93.5%) patients (p = 0.002). The difference in treatment decisions was not statistically significant between 18F-FDG PET/CT and WBMRI (p = 0.08). Conclusion Compared to 18F-FDG PET/CT, WBMRI had a higher per patient sensitivity for bone disease. However, treatment decisions were not statistically different and either modality would be appropriate in initial staging, depending on local availability and expertise.

POSITRON EMISSION TOMOGRAPHY WITH 18F -FDG IN THE DIAGNOSIS OF PROSTHETIC HEART VALVE ENDOCARDITIS

2021 ◽  
Vol 5 (1) ◽  
pp. 1151-1160
Author(s):  
A.S. Lukashevich ◽  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Fdg Pet ◽  
Prosthetic Heart Valve ◽  
Emission Tomography ◽  
Whole Body ◽  
Positron Emission ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Purpose. The purpose of the article is to evaluate the diagnostic significance of positron emission tomography / computed tomography with 18F -fluorodeoxyglucose (18F -FDG PET/CT) for the diagnosis of prosthetic endocarditis. Methods of research. The study included 82 patients with suspected prosthetic endocarditis in accordance with the criteria proposed by Duke University [1-5]. The patients received hospital treatment at the State Institution RSPC "Cardiology" from January 2016 to March 2021. The study was of a prospective, non-randomized, single-center cohort design. The duration of the monitor period was 12 months from the moment of patients’ inclusion in the study. Whole-body positron emission tomography / computed tomography (PET/CT) examinations were performed in 82 patients. 27 patients were selected for surgical treatment. Conservative treatment group included 16 patients. 27 patients were selected into the observation group, they were suspected to have prosthetic heart valve infection in the primary referral and underwent PET/CT scanning, according to which the diagnosis of prosthetic endocarditis was excluded. The event under the study did not develop in this group during the year of observation. Results and conclusion. The history of infective endocarditis was not statistically significant and did not increase the risk of developing prosthetic endocarditis in the sample presented. The Duke criteria are less reliable in establishing the diagnosis of prosthetic endocarditis. The median number of days from the date of the first prosthesis implantation to the onset of prosthetic endocarditis was about 4 years. This study revealed that the development of the infectious process in the area of the prosthesis was noted in a more distant postoperative period compared to literature data. Histological confirmation of infection was noted in 100% (27 patients) of cases in reoperated patients. The presence of a more formidable complication such as valve ring abscess located mainly in the projection of the aortic valve ring was quite common in both groups. Presepsin and Interleukin-6 have a statistically significant (U = 394,50 p = 0,01 and U = 94,50 p = 0.004) value in the prognosis of prosthetic endocarditis. Considering the data obtained from ROC analysis, it can be said that the cut-off point at which it is possible to diagnose prosthetic endocarditis based on PETCT is 2.85. The presented methods for the interpretation of whole-body FDG-PET/CT images of patients with suspected infectious complications after cardiac surgery, as well as with the presence of prosthetic endocarditis, show high sensitivity and specificity.

National survey of patient doses from whole-body FDG PET-CT examinations in France in 2011

2012 ◽  
Vol 152 (4) ◽  
pp. 334-338 ◽  
Author(s):  
C. Etard ◽  
D. Celier ◽  
P. Roch ◽  
B. Aubert
Keyword(s):  
National Survey ◽  
Fdg Pet ◽  
Whole Body ◽  
Pet Ct ◽  
Patient Doses ◽  
Fdg Pet Ct

scholarly journals Leydig cell tumor of the testis: an incidental finding at 18F-FDG PET/CT imaging

2021 ◽  
Vol 52 (1) ◽  
Author(s):  
Almalki Yassir
Keyword(s):  
Leydig Cell ◽  
Fdg Pet ◽  
Chronic Rejection ◽  
Ct Imaging ◽  
The Body ◽  
Whole Body ◽  
Pet Ct ◽  
18F Fdg ◽  
The Right ◽  
Fdg Pet Ct

Abstract Background Leydig cell tumors (LCTs) represent the most common form of stromal tumors. We reported the 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) findings of a patient with testicular LCT. Case presentation A 50-year-old man with a history of end-stage renal disease and renal transplantation 19 years ago. One year earlier, he started to have a chronic rejection. During the investigation to determine the cause of chronic rejection, a suspicious lesion in the graft with a collection around it was seen on ultrasound (US) images, raising the possibility of post-transplant lymphoproliferative disorder (PTLD). The patient was referred for further evaluation by whole body 18F-FDG PET/CT imaging. The image finding revealed an incidental hypermetabolic focal lesion in the right testicle—no other specific findings in the remaining parts of the body nor definitive FDG avid lymphadenopathy to suggest PTLD. Testicular US was requested and showed a well-defined right-sided heterogeneous hypoechoic intratesticular focal mass at the upper pole of the right testis with significant internal vascularity on the color Doppler imaging. The patient underwent a right radical orchidectomy, and the tumor was pathologically confirmed as an LCT. Conclusion In our case, 18F-FDG-PET/CT has been helpful in incidentally detecting this rare testicular tumor in a patient with suspected PTLD.

Sign in / Sign up

Export Citation Format

Share Document